COGT vs INCY
COGT: Cogent Biosciences is a clinical-stage biotechnology company developing precision protein kinase inhibitors, primarily targeting KIT mutations for the treatment of systemic mastocytosis and other cancers. INCY: A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating substantial cash flow.
Side-by-side fundamentals
| Metric | COGT | INCY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $39.54 | $115.79 | |
| Market cap as of 2026-07-23 | $6.8B | $23.3B | |
| P/E as of 2026-07-23 | n/a | 16.29 | |
| PEG as of 2026-07-23 | n/a | 1.00 | |
| Net margin as of 2026-07-23 | -264.1% | +26.7% | INCY higher |
| Gross margin as of 2026-07-23 | n/a | +93.0% | |
| Operating margin as of 2026-07-23 | -295.8% | +30.1% | INCY higher |
| ROE as of 2026-07-23 | -83.3% | +29.2% | INCY higher |
| ROA as of 2026-07-23 | -55.8% | +21.6% | INCY higher |
| Debt / equity as of 2026-07-23 | 0.37 | 0.01 | INCY lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +21.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.8% | |
| Beta as of 2026-07-23 | 0.33 | 0.77 | |
| 1-year return as of 2026-07-22 close | +222.3% | +74.2% | COGT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.